Printer Friendly

Ipsen Strikes Alliance with the Erasmus University Medical Centre Rotterdam.

PARIS -- Ipsen (ISIN:FR0010259150) (Paris:IPN) today announced it acquired an international patent application filed on 13th April 2006 owned by Erasmus University Medical Center Rotterdam (Erasmus MC), the Netherlands, for the co-administration of a somatostatin analogue with a growth hormone antagonist for the treatment of acromegaly. The application is based on clinical findings by Professor van der Lely, Head of Endocrinology in the Department of Internal Medicine at Erasmus MC. Preliminary clinical data1 suggest that the combined treatment of acromegaly with monthly long-acting somatostatin analogue(s) and weekly subcutaneous pegvisomant administrations is effective, might increase compliance and could greatly reduce the costs of medical treatment in some patients.

Under the terms of the agreement, Ipsen will pay Erasmus MC an upfront payment of [euro]1.25 million and up to [euro]8.75 million in additional milestone payments if certain conditions are met, including milestone payments notably upon patent issue and market approvals of the product for the corresponding indication.

"The alliance with Erasmus MC illustrates our strong partnership policy with world leading universities in the field of life sciences. This partnership allows Ipsen to further strengthen its position in endocrinology, and illustrate our commitment to offer state of the art treatment to acromegalic patients and to provide endocrinologists with optimal therapeutic choices" said Jacques-Pierre Moreau, Executive Vice-President, Chief Scientific Officer of Ipsen.

About Ipsen

Ipsen is a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), which are growth drivers and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four R&D centers (Paris, Boston, Barcelona and London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2005, Research and Development expenditure reached EUR 169 million, i.e. 20.9% of consolidated sales, which amounted to EUR 807 million in the Group's pro forma accounts set up according to the IFRS. Nearly 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext (stock code: IPN, ISIN code: FR0010259150). Ipsen's internet website is

About Erasmus MC - University Medical Center Rotterdam

The Faculty of Medicine and Health Sciences of Erasmus University Rotterdam and the University Hospital Rotterdam have joined forces to form Erasmus MC.

The largest centre of its kind in the Netherlands, Erasmus MC provides advanced medical care to 3 million people living in the southwestern part of the Netherlands. Care is organized in three clinical branches: the General Hospital; the Sophia Children's Hospital; and the Daniel den Hoed Oncology Center. Erasmus MC has achieved excellence in many areas, including cardiovascular diseases, oncology, paediatrics, cell biology & genetics, clinical genetics, human reproduction, endocrinology, microbiology, virology, immunology, hepatology and (micro-) surgery. Erasmus MC is among the top research institutes in the Netherlands and participates in several nationally and internationally recognized research schools. Research activities range from fundamental biomedical research, patient-related research and epidemiology to public health, health care policy and management. Erasmus MC offers basic medical education, followed by specialization tracks to become a general practitioner or a medical specialist. In addition, Erasmus MC offers Master of Science programs, postgraduate courses and researcher training courses.

The Erasmus MC employs over 10.000 people and is located at the North bank of the Maasriver in Rotterdam.

Forward-looking statements

The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein.

Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French Autorite des marches financiers.

1 The Lancet, 7 May 2005 ; 365 (9471): 1644-1646
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 24, 2007
Previous Article:TSYS Acquiring Solutions Signs Processing Agreement with Clearent.
Next Article:Expectations Decline - Only 37 Percent of U.S. Small Business Owners Predict Strong Valentine's Day Sales in 2007 - According to Constant Contact...

Related Articles
Paraphrase on Acts.
Endangered seals suffer massive die-off.
Do carrots ward off heart attacks?
De geschiedenis van de kindergeneeskunde in Nederland. Deel I: de periode tot 1700.
UN demobilised. (View).
SARS virus' genome hints at independent evolution. (Out of China).
"Linking PCBs to play behaviors of Dutch girls and boys": Vreugdenhil et al.'s response. (Correspondence).
"Dutch girls and boys: response from Vreugdenhil et al. (Correspondence).

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters